



Biotech Daily

Thursday September 25, 2014

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: ELLEX UP 9.5%, ANTISENSE DOWN 21%**
- * **ANTISENSE PLACES \$1m, PLAN FOR \$1.5m MORE**
- * **REGENEUS RECEIVES \$3.7m FEDERAL R&D TAX REFUND**
- * **JASON PETERSON, PROFESSIONAL PAYMENT TAKE 14% OF SUN BIO**
- * **DELOITTE, BIO-PHARMACEUTICALS AUSTRALIA ROADSHOW**

MARKET REPORT

The Australian stock market was up 0.12 percent on Thursday September 25, 2014 with the S&P ASX 200 up 6.4 points to 5,382.2 points.

Thirteen of the Biotech Daily Top 40 stocks were up, 10 fell, 10 traded unchanged and seven were untraded. All three Big Caps were up.

Ellex was the best, up three cents or 9.5 percent to 34.5 cents with 41,968 shares traded.

Anteo climbed 8.7 percent; Acrux and Bionomics were up more than six percent; Alchemia rose 4.9 percent; Cellmid, Compumedics and Osprey were up more than three percent; Benitec, Nanosonics and Prana rose more than two percent; Neuren was up 1.2 percent; with Cochlear, CSL, Resmed and Sirtex up by less than one percent.

Antisense led the falls, down three cents or 20.7 percent to 11.5 cents with 2.1 million shares traded.

IDT lost 8.3 percent; Clinuvel and Genetic Technologies fell more than seven percent; Tissue Therapies was down 5.5 percent; Biotron and Circadian fell more than four percent; Admedus was down 3.2 percent; Avita shed one percent; with Mesoblast down 0.45 percent.

ANTISENSE THERAPEUTICS

Antisense says it has raised \$1 million in a placement at 11.5 cents a share and hopes to raise a further \$1.5 million in a share purchase plan.

Antisense said that the funds would be used to progress partnering plans for ATL1103 for acromegaly, US Food and Drug Administration interactions on a potential phase IIb study for ATL1102 for multiple sclerosis and the planned higher dose clinical trial of ATL1103 in acromegalic patients.

The company said that its board and management participated in the placement for \$100,000 and also intended to participate in the share plan pending shareholder approval and US-based consulting and advisory firm Destum Partners, which was working with Antisense on partnering plans, received an allocation in the placement to the extent of fees due and payable to them.

Antisense said that Patersons Securities was the lead manager to the placement and lead manager and proposed underwriter to the share plan.

The company said that shareholders at the record date of September 24 would be able to subscribe for up to \$15,000 of new shares.

Antisense said that the plan was targeting a raising of \$1.5 million and would be underwritten by Patersons Securities to \$1 million, subject to execution of the final underwriting agreement.

The company said that following completion of the capital raising, it would no longer require the bridging loan from Macquarie Bank and expected to terminate the facility without draw down, on receipt of the Federal Government R&D Tax Incentive, expected in November (BD: Jun 2, 2014).

Antisense said that more than 12 companies were "actively evaluating the opportunity" of partnering ATL1103 for acromegaly.

Antisense managing director Mark Diamond said that "while the board has consciously sought to keep the size of the raising to a level that minimizes dilution ... raising this overall amount is [expected] to fund the company to the end of 2015 based on planned activities".

Antisense fell three cents or 20.7 percent to 11.5 cents with 2.1 million shares traded.

REGENEUS

Regeneus says it has received \$3.7 million from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Regeneus said the rebate related to research and development expenditure for the year to June 30, 2014

Regeneus fell two cents or 7.1 percent to 26 cents.

SUN BIOMEDICAL

Jason Peterson and Professional Payment Services say they have increased their holding in Sun Biomedical from 39,022,535 shares (11.78%) to 56,457,209 shares (13.65%).

In the substantial shareholder notice, the Perth, Western Australia based Mr Peterson said that 26,021,732 shares were acquired for \$264,250 or an average of one cent a share.

Mr Peterson and Celtic Capital have previously invested in Helicon Group, later Consegna Group, now Rhinomed, as well as Imugene, Acuvax and Narhex Life Sciences.

Sun was unchanged at 0.9 cents with one million shares traded.

[BIO-PHARMACEUTICALS AUSTRALIA, DELOITTE TOUCHE TOHMATSU](#)

Bio-Pharmaceuticals Australia and Deloitte are conducting a roadshow on bio-pharmaceutical development ending in Melbourne on October 9, 2014.

A media release from the Deloitte Touche Tohmatsu accountancy and advisory firm said it was hosting the event, sponsored by Queensland Government-backed industry organization Bio-Pharmaceuticals Australia.

Deloitte said that the roadshow would include presentations from Deloitte and Bio-Pharmaceuticals Australia, as well as from the University of Queensland's Australian Institute for Bio-engineering and Nanotechnology National Biologics Facility, Clinical Network Services, the Wolsrode, Germany-headquartered and Brisbane-based ERA Consulting, Pharmasynth, Tetraq and Q-Pharm

The Deloitte media release said that the event would showcase a sample of Australia's bio-pharmaceutical service capabilities to help organizations overcome challenges with drug development and to encourage interstate partnership.

Deloitte said that the event was aimed at bio-therapeutic developers and would provide insight from a range of service providers able to provide guidance on the road to market, from accessing non-dilutive funding under the Federal Government R&D Tax Incentive and the Bio-pharmaceutical Development Fund, to preclinical and clinical services, trial co-ordination, regulatory advice, and Australia's biologic manufacturing capabilities.

The Melbourne roadshow will be held at the offices of Deloitte Touche Tohmatsu at 550 Bourke Street, Melbourne, on October 9, 2014, with doors opening at 5.15pm for a 5.30pm start until 7.30pm.

For any queries contact Dr Gabriel Liberatore on + 613 9671 6096 or email biopharmaroadshow@deloitte.com.au.

For more information on Bio-Pharmaceuticals Australia or the Biopharmaceutical Development Fund, go to: www.biopharmaus.com.au.